Comparison of Proton Pump Inhibitor and H2 Receptor Blocker on Prevention of Bleeding From Iatrogenic Ulcer After Endoscopic Submucosal Dissection for Gastric Neoplasms: A Prospective Randomized Controlled Trial
Conditions
Delayed Bleeding
Conditions: official terms
Hemorrhage - Stomach Neoplasms
Study Type
Interventional
Study Phase
N/A
Study Design
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention
Intervention
Name: high dose proton pump inhibitor Type: Drug
Name: H2RB Type: Drug
Overall Status
Recruiting
Summary
after endoscopic submucosal dissection(ESD) of early gastric cancer, conventional proton pump(PPI) inhibitors and H2 receptor antagonists have a controversial effect on preventing bleeding from artificial ulcers. the aim of this study was to investigate whether a stronger acid suppression (high dose PPI) more effectively prevents bleeding after ESD
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 80 Years
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- the patients who agreed informed consent

- gastric adenoma or early gastric cancer which is eligible for conventional ESD indication

Exclusion Criteria:

- recent drug history of PPI, H2 rector antagonist, bismuth and antibiotics within 4 weeks

- recent drug history of anticoagulant or antiplatelet agent within 7 days

- s/p subtotal gastrectomy

- recurred gastric adenoma or cancer

- pregnant or breast feeding patients
Location
Samsung Medical Center
Seoul, Korea, Republic of
Status: Recruiting
Contact: Jae J Kim, Professor - 82-2-3410-3409 - jjkim@skku.edu
Start Date
July 2009
Completion Date
September 2010
Sponsors
Samsung Medical Center
Source
Samsung Medical Center
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page